Latest News - Amgen
Top Corporates Hub
Amgen
3 Dow Jones Stocks with Solid Fundamentals
24.07.2026 17:45
The Dow Jones (^DJI) is packed with iconic businesses that have built strong brands and durable market positions. A select few continue to thrive, delivering solid returns and proving their resilience in an evolving market.
Sanofi halts development of troubled immune drug in eczema
24.07.2026 11:35
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue “strategic action” to boost its pipeline.
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
24.07.2026 01:32
Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers.
Amgen Inc (NASDAQ:AMGN) Shows Technical Strength and Breakout Setup
23.07.2026 11:40
Amgen (AMGN) shows strong technical health with a 7/10 rating and a high-quality 9/10 setup pattern, signaling a potential breakout from consolidation near support.
Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced?
22.07.2026 04:29
A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen (AMGN) and is refocusing attention on the stock’s earnings setup. See our latest analysis for Amgen. Beyond the court ruling, Amgen’s share price has quietly built positive momentum, with a 30 day share price return of 8.48% and year to date share price return of 11.78%, while the 1 year total shareholder return of 23.41% and 3 year total shareholder return of 70.66%...
Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
14.07.2026 15:51
Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very different bets on the future of oncology. Pfizer is monetizing its Seagen deal today. Amgen is defending a biosimilar cliff while spending to rebuild growth from scratch. Padcev Carries Pfizer. Biosimilars Bite Amgen. Pfizer’s oncology ... Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
HRMY vs. AMGN: Which Stock Is the Better Value Option?
14.07.2026 15:40
HRMY vs. AMGN: Which Stock Is the Better Value Option?
Amgen (AMGN) Stock May Be 47% Undervalued After Enbrel Price Cap Ruling
14.07.2026 15:13
Amgen stock has delivered a strong 73.5% return over the last three years, and the current checks suggest a mixed picture on value, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to upside while market based multiples look closer to fair. Over three years, Amgen has returned 73.5%, which puts recent price action in focus when judging how much upside may still be left in the valuation. The recent court decision blocking Colorado's proposed price cap on...
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
09.07.2026 08:46
Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly.
Amgen (AMGN) Recalls Put Its Valuation Story Back In Focus
08.07.2026 03:15
Amgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...
The Cancer Therapy Strategy VERAXA Is Betting the Company On
06.07.2026 16:00
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
06.07.2026 16:00
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
06.07.2026 13:40
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
Amgen (AMGN) Stock Is Up, What You Need To Know
03.07.2026 00:28
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.1% in the afternoon session after the company received a favorable court ruling that blocked a first-of-its-kind state price cap on its blockbuster drug, Enbrel.
Roche KRAS drug succeeds in head-to-head lung cancer study
02.07.2026 10:19
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
02.07.2026 05:50
Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.
Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown
01.07.2026 11:06
This further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny.
Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran
01.07.2026 10:15
Amgen Inc. (NASDAQ:AMGN) ranks among the top NASDAQ stocks for retirement. On June 16, Mizuho increased its price target for Amgen Inc. (NASDAQ:AMGN) to $303 from $295 while keeping a Neutral rating on the company’s shares, with the firm highlighting MariTide and olpasiran as crucial focal points for the company. Mizuho said that Novartis and […]
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
30.06.2026 09:03
Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.
Amgen (AMGN) Stock Weighs Strong Run Against Mixed Valuation Signals
30.06.2026 08:15
If you are wondering whether Amgen stock still offers value at current levels, this article walks through what the numbers are actually saying about the price you see on screen. Amgen shares last closed at US$360.55, with returns of 3.9% over the past week, 7.1% over the past month, 10.0% year to date, 27.8% over one year, 75.7% over three years, and 73.2% over five years. This gives investors plenty of price history to weigh against today’s valuation. Recent attention on Amgen has been...